Duchenne Muscular Dystrophy
-
A Single CRISPR Treatment Can Show Significant Benefits In Mice With DMD
-
Dog Gene Editing Study Could Lead To Future Treatment For Human Muscular Dystrophy
-
Muscular Dystrophy Drug Price Jumps From $1,200 To $89,000 After FDA Approval
-
Corticosteroid Emflaza Receives FDA Approval As Duchenne Muscular Dystrophy Treatment
-
FDA Grants Accelerated Approval For Sarepta Muscular Dystrophy Drug Eteplirsen
-
BioMarin To Halt Development Of $680M Duchenne Muscular Dystrophy Drug
-
FDA Panel Gives Thumbs Down To Sarepta Duchenne Muscular Dystrophy Drug Eteplirsen
-
FDA Wants Advisory Panel To Vote On Sarepta Muscle Wasting Drug Eteplirsen
-
FDA Rejects BioMarin Pharmaceutical's Duchenne Muscular Dystrophy Drug
-
Successful Use Of Gene Editing Tool CRISPR In Live Mammals Spurs Hope For Duchenne Muscular Dystrophy Cure
-
FDA Panel Not Persuaded By Effectiveness Of BioMarin Duchenne Muscular Dystrophy Drug
-
Stem Cell Discovery Could Lead To Effective Treatments For Duchenne Muscular Dystrophy
Most Popular
